SBRT symposium 2019
We are pleased to announce the program for the 6th SBRT symposium on Stereotactic and Adaptive radiotherapy. Stereotactic ablative body radiotherapy (SABR) is now essential aspect of modern multidisciplinary cancer care. With the results of SABR-COMET and other randomized trials emerging, more national guidelines are expected to incorporate SABR as a treatment option, making knowledge and availability of SABR essential for all radiation oncologists. The clinical use of adaptive radiotherapy has also increased markedly in the past 3 years, both with and without guidance using on table MR imaging. Emerging data from on-table, adaptive SABR delivery since 2016 has revealed meaningful benefits in selected patient groups, which in turn requires other departments to formulate their own strategies for implementing adaptive radiotherapy.
The symposium was always highly appreciated by more than 250 participants from more than 30 countries. For more information and registration, go to: www.sbrt.eu
For any queries relating to this event please contact: